Funded Tech Companies
HepaRegeniX
HepaRegeniX, operating out of Tübingen, received investment capital through Boehringer Ingelheim Venture Fund, Vesalius Biocapital and High-Tech Gründerfonds.
Company Overview
Company Name
HepaRegeniX
Company Status
Private & Independent
Industry
Life Sciences
Funding Rounds
Total Funding
Contact Information
Mailing Address
Eisenbahnstraße 63
Tübingen, 72072
Germany
Tübingen, 72072
Germany
Phone
Website
Email Address
Company Background Information
Overview
HepaRegeniX GmbH is a clinical stage company developing novel therapies for the treatment of acute and chronic liver diseases. Since its start in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular target Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
7/10/2024
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Operating Officer
Wolfgang Albrecht
Chief Scientific Officer
Birgit Jung
Company Investors
- Boehringer Ingelheim Venture Fund
- Vesalius Biocapital (Fabienne Roussel)
- High-Tech Gründerfonds
- Novo Holdings
Browse more funded tech companies:
Share this article
About Our VC Funding Database
This venture capital transaction data comes via a partnership with VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs